News | July 21, 2022
DS-7300 Phase 2 Trial Initiated in Patients with Pretreated ExtensiveStage Small Cell Lung Cancer
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
The company now exceeds the sector benchmark for its overall ESG rating and for all three measures
Lupin Diagnostics will equip doctors with accurate diagnosis in the patient journey by leveraging innovative technologies
Tobacco smoke increases infant morbidity and is fatal to a baby because it damages the baby’s organs
Strand Life Sciences has sequenced a total of 12800 samples from July, 2021 to June, 2022, and identified more than a 100 lineages circulating in Bengaluru
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
She joins Enveda from Gilead Sciences
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
Subscribe To Our Newsletter & Stay Updated
